Dupixent access in Egypt: the EDA named-patient pathway
How Egyptian patients legally obtain Dupixent (dupilumab) when the locally registered indication, stocked pen presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Dupixent (dupilumab) is an interleukin-4 receptor alpha blocker approved by the US FDA across six type 2 inflammatory indications: atopic dermatitis from 6 months of age and up, moderate-to-severe asthma with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis in patients 1 year and older, prurigo nodularis, and COPD with type 2 inflammation. Dupixent is registered through the Egyptian Drug Authority (EDA), yet Egyptian families regularly use the EDA personal-import pathway to bridge gaps that local registration alone does not close: a pediatric atopic dermatitis case in an infant or toddler, a weight-banded pen presentation the local agent does not consistently stock, a payer denial on the asthma or EoE indication, or a COPD case where the 2024 US label has not yet translated into local reimbursement. Reserve Meds coordinates the US-side sourcing, the international cold-chain logistics to Cairo, and the documentation packet your physician needs.
Reserved for you.
Why Egyptian patients need Dupixent through the named-patient pathway
Egypt operates one of the largest pharmaceutical markets on the African continent and one of the most active named-patient import workflows in the Arab world. The country imports roughly USD 3 billion in finished drug product annually, and a meaningful share of that demand sits inside small, named-patient cases rather than mass-market supply. For Dupixent specifically, Egyptian families rarely ask for a drug that does not exist locally. They typically ask for a precise version of it that the local route has not caught up to, or that local payers will not fund.
Four converging patterns drive these cases. First, indication lag. Newer Dupixent indications, especially pediatric atopic dermatitis under 6 years, pediatric EoE under 12 years, prurigo nodularis, and COPD with type 2 inflammation, often reach local registration 12 to 36 months after FDA approval. A Cairo dermatologist documenting severe atopic dermatitis in a 2-year-old fits the US label but may not fit the current EDA-registered indication. Second, weight-banded pen gaps. A 25 kg child needing the 200 mg pen may find only the 300 mg pen on local shelves. Third, payer denial. Bupa Egypt, AXA Egypt, MetLife Egypt, Allianz Egypt, Misr Insurance, MedGulf Egypt, Orient Takaful, and Royal Insurance each assess specialty biologics case by case, and many private plans will not fund type 2 inflammation indications even where the drug is registered. The post-2022 EGP depreciation has made imported specialty therapies significantly more expensive in local-currency terms, which is one reason cash-pay families increasingly coordinate USD funds from relatives in the Gulf, Europe, or North America. Fourth, brand familiarity. Heavy US direct-to-consumer advertising has built strong patient awareness across MENA and Egyptian diaspora populations.
In each pattern, the EDA personal-import pathway is the mechanism that connects an Egyptian-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient.
The EDA named-patient pathway for Dupixent
The Egyptian Drug Authority was created by Law No. 151 of 2019, issued 25 August 2019 in the Official Gazette No. 34 bis (A), with executive regulations issued by Prime Minister Decision No. 777 of 2020. EDA consolidates functions previously held by NODCAR, NORCB, and the Ministry of Health's Central Administration of Pharmaceutical Affairs. The EDA Drug Registration Sector handles registration files, and the Egyptian Pharmacovigilance Center (EPVC) handles post-market safety.
EDA permits the importation of unregistered medicines for a specific patient under defined conditions, most importantly where no equivalent registered product is available locally, or where the available quantity of an equivalent registered product cannot meet the patient's clinical need. This pathway is commonly referred to as Personal Importation, sometimes described in EDA correspondence as Special Access or Compassionate Use. The application is filed through the dispensing institution's import pharmacy, typically a private specialty hospital, a university hospital import desk, or a licensed specialty importer acting on the patient's behalf.
The standard application package includes a clinical justification letter from the treating physician (original, stamped, on hospital letterhead, stating the diagnosis, severity, prior therapies attempted and failed, and the specific clinical reason this drug is required rather than a locally available alternative), a recent prescription specifying brand name, generic name (INN), strength, dosage form, and quantity required, a patient identifier (copy of the national ID card or passport), physician licensing verification (Egyptian Medical Syndicate membership number and Ministry of Health licence reference), full product details (manufacturer name, country of origin, FDA approval reference, shelf life, storage conditions), the destination dispensing facility licence, and a chain-of-custody plan including cold-chain documentation, customs and freight forwarder identification, and expected port of entry (typically Cairo International Airport for air freight).
For Dupixent, the clinical justification angle typically rests on one of three documented elements. For a pediatric atopic dermatitis case under 6 years, the prescriber documents the FDA-approved age indication, severity (commonly EASI score and IGA), and the local indication gap. For a denied biologic claim on asthma, EoE, or COPD, the prescriber documents prior step-therapy failure and the type 2 inflammation phenotype (blood eosinophil count, IgE level, or biopsy finding where relevant). For a weight-banded pen request, the prescriber specifies the exact 100 mg, 150 mg, 200 mg, or 300 mg presentation required and the weight band that drives the choice. One Egypt-specific clinical note belongs in the letter: where the patient has documented or epidemiologically plausible helminth exposure (Egypt remains a region with historical schistosomiasis burden among other helminth infections), the prescriber records baseline assessment and treatment of any active helminth infection before initiating dupilumab, in line with the FDA label precaution that the antibody may impair the immune response to helminths.
Routine EDA personal-import authorisations for well-documented cases are typically processed in a 3 to 6 week window once a complete package is submitted. Complex cases or first imports of a given pediatric pen format can extend to 8 to 14 weeks. EDA reserves discretion at every step, and we do not promise specific durations.
Where Dupixent gets dispensed in Egypt
The Egyptian hospitals that handle named-patient imports as routine workflow, with established import pharmacy infrastructure and cold-chain biologic storage capacity, span both academic and private sectors. For Dupixent, dispensing facilities must maintain 2 to 8 degrees Celsius refrigerated storage with continuous monitoring. The most relevant institutions for Reserve Meds Dupixent cases include Cairo University Hospitals (Kasr Al Ainy) for dermatology, allergy, and pediatric specialty cases routed through its Drug Information Center; Ain Shams University Hospitals for adult and pediatric hepatology, dermatology, and respiratory specialty services; Dar Al Fouad Hospital (6th of October City, Giza), a JCI-accredited private super-specialty hospital with strong outpatient pharmacy infrastructure; As-Salam International Hospital in Cairo; the Cleopatra Hospitals Group network, the largest private hospital group in Egypt with multiple Cairo facilities; and the Children's Cancer Hospital Egypt 57357 for pediatric specialty workflows where applicable.
For physicians at smaller hospitals or outpatient clinics in Alexandria, Giza, or regional governorates, the practical route is partnering with a Cairo-based licensed specialty importer that handles the EDA filing, customs clearance, and final delivery to a licensed dispensing facility. The importer holds the dispensing pharmacy licence; the clinical justification still comes from the treating physician.
Real cost picture for Dupixent in Egypt
US WAC for Dupixent is approximately USD 3,993 per 300 mg pen carton (two-pack) as disclosed by Sanofi in January 2025, which translates to an annual WAC in the range of USD 37,000 to USD 43,000 for the most common adult atopic dermatitis regimen (300 mg every 2 weeks, 26 doses per year). Reserve Meds quotes in USD and accepts USD wire transfers. The EGP has lost more than 70 percent of its value against the US dollar since early 2022, with the USD/EGP rate near 52 to 53 in May 2026 per IMF Article IV consultation reference. Quoting in USD insulates the patient from intra-case currency drift between firm quote and shipment.
International cold-chain logistics from a US source to Cairo typically runs USD 400 to USD 1,500 depending on pen-format volume, temperature class, and route. Regulatory documentation handling fees on the Egyptian side vary by dispensing facility and importer. Reserve Meds' concierge fee is itemised separately on every firm quote, never bundled.
On the insurance side, each Egyptian insurer assesses named-patient imports case by case. Bupa Egypt and AXA Egypt commonly require pre-authorisation; some plans reimburse a percentage when the drug treats a covered indication even if the specific product is not on a local formulary. The Universal Health Insurance Authority (UHIA) rollout under Law No. 2 of 2018 is governorate-phased through 2032 and does not currently cover most specialty imports for most patients. We supply the documentation set that allows your insurer or hospital to assess the claim; the claim filing itself stays with you or your dispensing hospital. The DUPIXENT MyWay copay card and US manufacturer patient assistance programs do not extend internationally.
Typical timeline for Dupixent in Egypt
EDA routine processing for well-documented Dupixent cases is typically 3 to 6 weeks from a complete filing, longer than the SFDA Personal Importation Program in Saudi Arabia or the EDE pathway in the UAE. For Dupixent, cold-chain shipment adds 2 to 3 days versus an ambient small molecule because validated thermal packaging, continuous temperature monitoring, and customs clearance at Cairo International Airport scheduled to avoid tarmac heat exposure are non-negotiable. End-to-end, most adult atopic dermatitis or asthma cases complete within 5 to 9 weeks from first complete documentation. Pediatric weight-banded cases or first imports of a given pen format may run slightly longer because EDA review can extend. The 14-day room-temperature excursion runway on the FDA label gives meaningful operational flexibility for the trans-Atlantic to Cairo lane, provided the cold chain is properly broken only at the dispensing pharmacy.
What your physician needs to provide
For an Egyptian-licensed dermatologist, pulmonologist, allergist, gastroenterologist, or pediatric specialist prescribing Dupixent through the EDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's diagnosis (atopic dermatitis with severity score, asthma with eosinophilic phenotype documented by blood eosinophil count, CRSwNP, EoE with biopsy confirmation, prurigo nodularis, or COPD with type 2 inflammation), prior therapy history including topical or systemic corticosteroids and prior biologics where relevant, and a clinical rationale for why dupilumab is the appropriate next step.
The letter also specifies the exact dosing plan per the FDA-approved label: 600 mg load then 300 mg every 2 weeks for adult atopic dermatitis; weight-banded dosing for pediatric atopic dermatitis (200 mg or 300 mg every 4 weeks below 30 kg; 200 mg every 2 weeks for 30 to 60 kg; adult dosing at 60 kg and above; 200 mg or 300 mg every 4 weeks for 6 months to 5 years by weight band); the asthma-specific regimen with appropriate loading dose for the phenotype; 300 mg every 2 weeks for CRSwNP and COPD; and the weekly or every-other-week EoE schedule depending on age and weight. The monitoring plan should reference baseline assessment for helminth infection in patients from endemic regions, ophthalmology follow-up if conjunctivitis develops, and continuation of background topical or inhaled therapy until the prescriber adjusts it.
The treating physician's Egyptian Medical Syndicate membership number, Ministry of Health licence reference, the dispensing facility licence, and the pharmacy in charge complete the package. Pharmacovigilance reporting through EPVC during therapy stays with the treating physician.
Common questions about Dupixent in Egypt
Will Bupa Egypt, AXA Egypt, MetLife, or Allianz cover this? Each insurer assesses named-patient imports case by case. Some plans reimburse a percentage when Dupixent treats a covered indication even if the specific product is not on a local formulary; many require pre-authorisation. Reserve Meds supplies the documentation an insurer needs to assess. The claim filing remains with the patient or the hospital. Cash-pay is the default posture, and many Egyptian families reimburse themselves later if coverage applies.
My child is 3 years old. Is the under-6 indication accessible? The FDA approved Dupixent for atopic dermatitis in infants and young children 6 months and older in June 2022. The local Egyptian indication may lag the FDA timeline; the EDA personal-import pathway exists precisely to bridge this gap when the local label has not caught up.
Do we need TB screening before starting Dupixent? Dupixent itself does not carry a TB screening requirement in its FDA label, in contrast to anti-TNF agents and JAK inhibitors. Your pulmonologist or allergist may still order baseline TB workup as part of standard moderate-to-severe asthma or biologic-initiation assessment, particularly where comorbidities warrant it, but it is a clinical judgment rather than a Dupixent label requirement.
What about helminth or schistosomiasis screening? The Dupixent FDA label flags a precaution: patients with known helminth infection should be treated before initiating Dupixent because dupilumab may impair the immune response to helminths. For Egyptian patients with possible exposure (rural water contact, historical schistosomiasis exposure, or other helminth risk), the prescriber documents baseline assessment and treats any active infection before starting therapy.
What about competitors like Adbry, Ebglyss, or Rinvoq? In atopic dermatitis, tralokinumab (Adbry) and lebrikizumab (Ebglyss) are alternative IL-13 pathway biologics, and JAK inhibitors such as upadacitinib (Rinvoq) and abrocitinib are oral alternatives. In asthma, omalizumab, mepolizumab, reslizumab, benralizumab, and tezepelumab sit in the same competitive set. Choice depends on phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed.
Can I receive Dupixent at home? The dispensing facility must hold a valid Egyptian pharmacy or hospital licence. The hospital outpatient pharmacy or licensed specialty importer pharmacy releases the pen to you after final verification, and you then administer the subcutaneous injection at home after training. Cold-chain handoff ends at the dispensing pharmacy; home refrigeration and injection-site rotation are part of your patient onboarding.
Where Reserve Meds fits in Dupixent cases
Reserve Meds is a US-based concierge coordinator. We do not replace your dermatologist, allergist, pulmonologist, or pediatrician, we do not replace EDA, we do not replace your dispensing pharmacy, and we do not act as an importer of record in Egypt. For Dupixent specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into Cairo, and assign a single named coordinator who runs the case end to end in both English and Arabic. No prior Reserve Meds Dupixent case is on file yet; standard NPP coordination under our cold-chain biologic playbook applies. Pediatric pen selection, weight-banded dosing confirmation, helminth-precaution alignment, and home-injection education are the recurring operational fundamentals we expect for this drug.
Next step
If your Egyptian physician has prescribed Dupixent and you are weighing the cross-border route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.